Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 4/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211931 | 0.88 | ANO1 (0.36) | ALDH1A1MAPTNPC1ABL1KDM4E | |
| SCHEMBL211736 | 0.87 | ALDH1A1 (0.34) | ALDH1A1MAPTNPC1ABL1KDM4E | |
| SCHEMBL212032 | 0.87 | ALDH1A1 (0.34) | ALDH1A1MAPTNPC1ABL1KDM4E | |
| SCHEMBL211154 | 0.86 | ALDH1A1 (0.33) | ALDH1A1MAPTNPC1ABL1KDM4E | |
| SCHEMBL210645 | 0.86 | NPC1 (0.39) | ALDH1A1MAPTNPC1KDM4ELMNA | |
| SCHEMBL2725125 | 0.85 | ABL1 (0.37) | NPC1ABL1ANO1 | |
| SCHEMBL209634 | 0.85 | ABL1 (0.34) | ALDH1A1ABL1P2RX7ANO1MAPK1 | |
| SCHEMBL210704 | 0.85 | DYRK1A (0.40) | ABL1 | |
| SCHEMBL210948 | 0.84 | ABL1 (0.33) | ALDH1A1MAPTNPC1ABL1MAPK8 | |
| SCHEMBL2723145 | 0.84 | NPC1 (0.38) | ALDH1A1MAPTNPC1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ALDH1A1 1710/4885MAPT 530/4885NPC1 4684/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | ALDH1A1 1710/4885MAPT 530/4885NPC1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.